March 20, 2026, marks a pivotal milestone for the Indian pharmaceutical industry as patents for Semaglutide (the active ingredient in Novo Nordisk’s Ozempic and Wegovy) officially expire. This event clears the path for over 40 domestic manufacturers to launch generic versions at unprecedented competitive prices.
Key market developments:
-
Race among pharma giants: Industry leaders such as Sun Pharma, Dr. Reddy’s, Cipla, and Biocon are poised to enter the market. Strategic alliances have already emerged, notably the collaboration between Lupin and Zydus, as well as Zydus and Torrent Pharmaceuticals, to optimize production and distribution capabilities.
-
Drastic price reductions: While branded versions range from 8,800 to 16,400 rupees ($94 – $175), companies like Natco have announced a shocking starting price of just 1,290 rupees ($13.79) per month.
-
Social and medical impact: With 90 million people living with diabetes (the second-largest population globally after China), the price drop is expected to make treatment accessible to middle-income patients, moving beyond the previously limited wealthy urban demographic.
-
Regulatory challenges: Experts warn of a “chaotic” short-term period driven by aggressive marketing campaigns and varying pen device quality. The risk of misuse for cosmetic purposes or unsupervised usage could lead to stricter regulatory oversight in the future.
India is serving as a real-world “test case” for the global market before major regions like the US and Europe face Semaglutide patent expirations in the 2031-2032 timeframe.